Yellow Root

Arcangelisia flava contains the protoberberine alkaloids palmatine and berberine, which inhibit microbial enzymes, suppress xanthine oxidase activity, and disrupt fungal cell function through high-affinity receptor binding. In vitro studies demonstrate antifungal minimum inhibitory concentrations of 15.62–62.5 µg/mL against Candida species and xanthine oxidase IC50 values as low as 30.44 ppm for stem extracts, approaching the potency of the pharmaceutical standard allopurinol (24.03 ppm).

Origin & History

Arcangelisia flava is a climbing liana native to the tropical rainforests of Southeast Asia, including Indonesia, Malaysia, the Philippines, and Thailand, where it grows in lowland and montane forest understories. The plant favors humid, shaded environments with rich, well-drained soils typical of equatorial rainforest ecosystems. Its woody roots and stems, which concentrate the highest densities of protoberberine alkaloids, are the primary plant parts harvested in both traditional and research contexts.

Historical & Cultural Context

Arcangelisia flava, called 'akar kuning' (yellow root) in Malay and Indonesian languages, has been integral to Jamu—the traditional herbal medicine system of Indonesia and Malaysia—for centuries, employed primarily against malaria, jaundice, and gastrointestinal infections including diarrhea. The plant's vivid yellow color, derived from berberine and palmatine pigments in the roots and stems, made it visually distinctive and contributed to its identification across diverse Southeast Asian ethnobotanical traditions including those of the Philippines and Thailand. In Borneo, the root decoction is documented among Dayak communities for febrile illnesses and liver complaints, while Filipino traditional healers have used it for skin infections and as a bitter tonic. The plant is referenced in Dutch colonial-era Indonesian pharmacopoeial records as part of indigenous pharmaceutical knowledge, predating the isolation of its active alkaloids by several centuries.

Health Benefits

- **Antifungal Activity**: Palmatine and fibraurin from root dichloromethane extracts exhibit molecular docking binding free energies of −6.64 and −6.71 kcal/mol respectively against fungal enzymatic targets, significantly outperforming ketoconazole (−1.70 kcal/mol) in silico, with in vitro MICs of 15.62–62.5 µg/mL against Candida species.
- **Xanthine Oxidase Inhibition**: Stem extracts inhibit xanthine oxidase—the enzyme converting hypoxanthine and xanthine to uric acid—with an IC50 of 30.44 ppm, suggesting potential utility in managing hyperuricemia and gout, comparable to the drug allopurinol at 24.03 ppm.
- **Antimalarial Properties**: Traditional Jamu medicine in Indonesia and Malaysia has long employed the roots for malaria treatment, consistent with the known antimalarial activity of berberine-class alkaloids that interfere with plasmodial DNA replication and mitochondrial function.
- **Antibacterial Effects**: Berberine isolated from A. flava demonstrates in silico activity against E. coli target protein 1UAG and S. aureus target 7RM7, with in vitro assays confirming greater antibacterial potency against E. coli than S. aureus, supporting traditional use in infectious diarrhea.
- **Antioxidant Capacity**: Ethyl acetate extracts yield an antioxidant capacity of 23.31 mgGAE/g (gallic acid equivalents), while methanol stem extracts contain 16.7 ppm total flavonoids, contributing to free radical scavenging alongside the alkaloid fraction.
- **Antidiarrheal Activity**: Used across Indonesian and Malaysian Jamu traditions for acute diarrhea, berberine's well-characterized ability to inhibit intestinal secretion, reduce gut motility, and exert direct antimicrobial effects against enteric pathogens provides a plausible mechanistic basis for this application.
- **Cytotoxic Potential**: Methanol extracts and isolated berberine show LC50 values of 89.13 µg/mL and 75.86 µg/mL respectively in Artemia salina brine shrimp toxicity assays, indicating bioactive cytotoxic properties that may be relevant to future antitumor investigation, though human data are absent.

How It Works

The principal bioactive alkaloids palmatine and berberine act through multiple complementary molecular mechanisms: both compounds intercalate into microbial DNA and inhibit topoisomerase II activity, disrupting replication in bacteria and fungi. Palmatine and the co-isolated compound fibraurin bind with high affinity to fungal enzymatic active sites, with molecular docking energies of −6.64 and −6.71 kcal/mol respectively, physically blocking substrate access and catalytic function. Berberine inhibits xanthine oxidase by occupying its molybdopterin cofactor-containing active site, reducing conversion of purines to uric acid—an effect corroborated by the stem extract IC50 of 30.44 ppm. Additionally, berberine activates AMP-activated protein kinase (AMPK) and suppresses NF-κB-mediated inflammatory signaling, mechanisms documented in the broader berberine literature that likely extend to A. flava-derived berberine.

Scientific Research

All available peer-reviewed evidence for Arcangelisia flava is preclinical, consisting exclusively of in vitro microbiological assays, in silico molecular docking studies, and brine shrimp cytotoxicity models; no human clinical trials have been published. Antifungal studies quantified MICs of 15.62–62.5 µg/mL and minimum fungicidal concentrations of 62.5–125 µg/mL against Candida species using isolated palmatine and fibraurin. Xanthine oxidase inhibition was assessed using spectrophotometric enzymatic assays, yielding IC50 values of 174.62 ppm for combined leaf-stem ethanol extract and 30.44 ppm for stems alone, with allopurinol as the reference standard at 24.03 ppm. The research base is narrow, geographically concentrated in Indonesian and Malaysian institutions, and lacks the pharmacokinetic, toxicological, and clinical translational data required to establish therapeutic dosing or safety in humans.

Clinical Summary

No human clinical trials investigating Arcangelisia flava or its isolated alkaloids as a standardized supplement have been identified in the peer-reviewed literature to date. The entirety of quantitative efficacy data derives from cell-free enzymatic assays, fungal culture MIC determinations, molecular docking simulations, and invertebrate (Artemia salina) toxicity screens. While these preclinical parameters are biologically plausible and internally consistent with the known pharmacology of berberine and palmatine, effect sizes and safety margins applicable to human supplementation cannot be derived from them. Confidence in clinical benefit is therefore low, and A. flava's current evidence base supports only hypothesis generation and traditional ethnopharmacological documentation rather than evidence-based therapeutic recommendation.

Nutritional Profile

Arcangelisia flava is not consumed as a food source and has no meaningful macronutrient content relevant to nutrition. Its primary bioactive constituents are protoberberine alkaloids, principally palmatine (isolated at 910 mg per root extraction batch) and berberine, along with the structurally related compound fibraurin (42 mg per extraction batch). Secondary phytochemicals include flavonoids (16.7 ppm total flavonoid content in methanol stem extract), diterpenoids, saponins, and terpenoids distributed across aerial and root tissues. Antioxidant phenolic content is measured at 23.31 mgGAE/g in ethyl acetate extract. Alkaloid bioavailability from whole plant preparations is expected to be low due to P-glycoprotein efflux and first-pass hepatic metabolism, consistent with patterns documented for berberine in related plant species, though no specific pharmacokinetic data for A. flava have been published.

Preparation & Dosage

- **Traditional Decoction (Root/Stem)**: Roots and stems are boiled in water in Indonesian and Malaysian Jamu practice for malaria, jaundice, and diarrhea; no standardized traditional dose has been formally documented in the peer-reviewed literature.
- **Dichloromethane Extract (Research Grade)**: Used to isolate palmatine (910 mg yield) and fibraurin (42 mg yield) per extraction batch from dried roots; this solvent system is not suitable for oral supplementation.
- **Methanol Extract (Research Grade)**: Applied to stems for xanthine oxidase inhibition studies and alkaloid profiling; total flavonoid content of 16.7 ppm identified; not a commercial supplement form.
- **Ethanol Extract**: Used in phytochemical screening and antioxidant assays; IC50 for xanthine oxidase inhibition of 174.62 ppm (combined leaf-stem) and 30.44 ppm (stems alone).
- **Ethyl Acetate Extract**: Antioxidant capacity of 23.31 mgGAE/g measured; employed in antimicrobial assays with MICs of 15.62–62.5 µg/mL.
- **Note on Standardized Dosing**: No commercial supplement form, standardization percentage, or evidence-based human dose range has been established; practitioners relying on berberine analogy may reference berberine HCl dosing (typically 500 mg TID in human trials) but this extrapolation is not validated for A. flava specifically.

Synergy & Pairings

Berberine-containing plants including A. flava are hypothesized to demonstrate enhanced antimicrobial efficacy when combined with efflux pump inhibitors such as piperine (from black pepper, Piper nigrum), as piperine blocks P-glycoprotein-mediated berberine efflux from cells, increasing intracellular alkaloid concentration and bioavailability. In the context of xanthine oxidase inhibition for hyperuricemia management, combining A. flava stem extract with quercetin-rich botanicals (e.g., Sophora japonica) may produce additive enzyme inhibition through complementary active-site and allosteric binding. Traditional Jamu formulations frequently combine A. flava with Curcuma species, where curcumin's NF-κB suppression and berberine's AMPK activation may provide complementary anti-inflammatory synergy.

Safety & Interactions

Berberine isolated from A. flava demonstrated cytotoxicity with an LC50 of 75.86 µg/mL in Artemia salina larval bioassays, and methanol extract showed LC50 of 89.13 µg/mL, indicating dose-dependent cytotoxic potential; however, no human adverse event data, maximum tolerated dose, or NOAEL has been established for A. flava preparations. Based on the pharmacology of its primary alkaloid berberine—extensively studied in other plant sources—potential concerns include inhibition of CYP3A4 and P-glycoprotein transporters, which could elevate plasma concentrations of co-administered drugs including cyclosporine, statins, and certain antibiotics. Berberine-class alkaloids are generally contraindicated in pregnancy due to documented uterotonic and potential embryotoxic effects in animal models, and are not recommended during lactation. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, severe hepatic impairment, or those taking anticoagulants, antidiabetic agents, or antihypertensives should exercise particular caution, and self-medication with A. flava preparations in place of proven antimalarial therapy is not medically appropriate.